Key facts
- This page summarizes William L. Ashton's Form 4 filing for Medicus Pharma Ltd. (MDCX).
- 1 reported transaction and 1 derivative row are listed below.
- Accepted by SEC: 04 Jun 2026, 16:00.
William L. Ashton - 03 Jun 2026 Form 4 Insider Report for Medicus Pharma Ltd. (MDCX)
- Reporting relationship
- Director
- Issuer ticker
- MDCX
- Reported as of
- 03 Jun 2026
- Net transaction value
- $0
- SEC form
- 4
- Accepted by SEC
- 04 Jun 2026, 16:00:21 UTC
- Prior SEC filing
- 01 Apr 2026
- Source filing
- View source filing
- Reporting owner signature
- /s/ Raza Bokhari, as Attorney-in-Fact, for William L. Ashton
Source evidence
Original filing metadata and source links for verification.
4 source fields
Reporting owner
1 detail
Key filing fact
William L. Ashton filed Form 4 for Medicus Pharma Ltd. (MDCX) on 04 Jun 2026.
Change
- Previous filing in this sequence was filed on 01 Apr 2026.
- Current net transaction value: $0.
Research use
- This tells you what this filing adds before you inspect full transaction and derivative tables.
- You can trace every row back to the original SEC filing document.
Evidence
Filed on Form 4
View source filing
Ownership activity is grounded in SEC Form 4 disclosures.
Reporting Owners (1)
CIK 0001474553
Primary reporting owner
Ashton William
- Relationship
- Director
- Address
- 300 CONSHOHOCKEN STATE ROAD, SUITE 200, W. CONSHOHOCKEN
- Signature
- /s/ Raza Bokhari, as Attorney-in-Fact, for William L. Ashton
- Signature date
- 04 Jun 2026
Reported derivative securities
Options, warrants, convertible securities, or similar derivative positions disclosed in the filing.
MDCX
transaction
Derivative
Stock Option (right to buy)
Award
- Transaction value
- Shares
- +50,000
- Change %
- Price
- $0.000000*
- Shares after
- 50,000
- Date
- 03 Jun 2026
- Ownership
- Direct
- Underlying class
- Common Shares
- Underlying amount
- 50,000
- Exercise price
- $0.3600
- Footnotes
- F1
* marks a reported price that did not pass the local price check.
Additional SEC filing notes
Filing notes and footnotes
Explanation of responses 1 footnote
Footnote F1
The option was granted on June 3, 2026. The option is scheduled to vest quarterly in four equal installments over one year.